Elizabeth Holmes won’t report to prison this week amid appeal; Walmart’s leaders must face investor litigation over company’s alleged role in fueling opioid epidemic; RNA startup Orbital Therapeutics raises $270 million in Series A funding.
Five things for pharma marketers to know: Wednesday, April 26, 2023
WHO warns that Sudanese violence brings “huge biological risk” to lab holding samples of deadly diseases; Danaher slashes annual sales growth forecast; Ideaya Biosciences plots $150 million initial public offering.
Five things for pharma marketers to know: Tuesday, April 25, 2023
Bluebird Bio submits application for sickle cell therapy lovo-cel to FDA; Foghorn Therapeutics study put on partial hold after serious heart-related safety event; Florida’s plan to get cheaper prescription drugs from Canada snarled in a legal back-and-forth.
Five things for pharma marketers to know: Monday, April 24, 2023
Eli Lilly expects CMS to back down from strict coverage limits on new Alzheimer’s drugs; Colorado bill capping the cost of EpiPens would let drugmakers offer alternatives to the state program; ‘Pharma Bro’ Martin Shkreli unveils a medical chatbot.
Five things for pharma marketers to know: Friday, April 21, 2023
The Supreme Court is under the microscope ahead of abortion pill ruling deadline; Lawmakers introduce a bipartisan framework to tackle pharmacy benefit managers; Pan American Health Organization talks with Takeda about dengue vaccine amid outbreak.
Five things for pharma marketers to know: Thursday, April 20, 2023
Leaked Phase III J&J study shows promise in CAR-T therapy Carvykti; Vaxcyte to raise $500 million to help fund Phase III for pneumococcal vaccine; Anti-abortion group Students for Life petitions FDA to restrict mifepristone due to environmental concerns.
Five things for pharma marketers to know: Wednesday, April 19, 2023
FDA clears way for second updated COVID-19 boosters; AstraZeneca confident in COVID antibody protecting against variants; Buffalo Bills player Damar Hamlin is “fully cleared” to play after seeing three specialists.
Five things for pharma marketers to know: Tuesday, April 18, 2023
Eli Lilly announces it will add another $1.6 billion and 200 jobs to its Boone County project; Danaher abandons pursuit of Catalent; Argentina sterilizes mosquitoes with atomic radiation as it battles a major dengue outbreak.
Five things for pharma marketers to know: Monday, April 17, 2023
U.S. charges sons of “El Chapo” with running a fentanyl trafficking operation fueled by Chinese pharmaceutical companies; Many baby formula claims have “little or no scientific” proof; Scientists reports a breakthrough in identifying Parkinson’s disease.
Five things for pharma marketers to know: Friday, April 14, 2023
The Biden administration asks Supreme Court to intervene in ruling restricting mifepristone; FDA was leaning toward rejecting Sarepta’s gene therapy for Duchenne muscular dystrophy; Merck eyes sale of pigments division.